93,434 Aktis Oncology $AKTS Shares Acquired by Mirador Capital Partners LP

Key Points

• Mirador Capital Partners increased its Aktis Oncology stake by 232.9%, acquiring 93,434 shares to own 133,558 shares worth approximately $2.6 million. Institutional investors collectively own 28.84% of the company.
• Analyst sentiment remains broadly positive: Aktis Oncology has a “Moderate Buy” consensus rating and an average price target of $35.62, despite one recent downgrade to “sell.”
• AKTS opened at $18.15, well below its 52-week high of $34.19. The company reported quarterly revenue of $3.38 million but posted an adjusted loss of $0.44 per share, slightly missing estimates.

Mirador Capital Partners LP raised its stake in Aktis Oncology (NASDAQ:AKTS - Free Report) by 232.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 133,558 shares of the technology company's stock after acquiring an additional 93,434 shares during the quarter. Mirador Capital Partners LP owned about 0.25% of Aktis Oncology worth $2,600,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of Aktis Oncology by 7.9% during the second quarter. BlackRock Inc. now owns 2,278,358 shares of the technology company's stock worth $73,431,000 after purchasing an additional 166,231 shares during the period. Tidal Investments LLC bought a new position in Aktis Oncology during the 2nd quarter worth $1,839,000. Alyeska Investment Group L.P. acquired a new stake in shares of Aktis Oncology during the second quarter worth $9,347,000. Wellington Management Group LLP acquired a new stake in shares of Aktis Oncology during the second quarter worth $63,372,000. Finally, Jupiter Topco LLC bought a new stake in shares of Aktis Oncology in the second quarter valued at about $42,359,000. Institutional investors own 28.84% of the company's stock.

Analyst Ratings Changes

AKTS has been the topic of a number of recent research reports. Wedbush reaffirmed an "outperform" rating and set a $35.00 price target on shares of Aktis Oncology in a research report on Friday, October 2nd. Oppenheimer initiated coverage on shares of Aktis Oncology in a research report on Wednesday, September 9th. They set an "outperform" rating and a $40.00 target price on the stock. JPMorgan Chase & Co. raised their target price on shares of Aktis Oncology from $30.00 to $33.00 and gave the stock an "overweight" rating in a report on Tuesday, July 14th. BMO Capital Markets initiated coverage on shares of Aktis Oncology in a research report on Tuesday, August 18th. They issued an "outperform" rating and a $37.00 price target for the company. Finally, Wall Street Zen cut Aktis Oncology from a "hold" rating to a "sell" rating in a research note on Saturday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $35.62.

Insider Transactions at Aktis Oncology

In other Aktis Oncology news, Director Ken Herrmann sold 4,856 shares of Aktis Oncology stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $24.56, for a total value of $119,263.36. Following the transaction, the director owned 3,506 shares in the company, valued at $86,107.36. The trade was a 58.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 3.30% of the stock is currently owned by corporate insiders.

Aktis Oncology Price Performance

NASDAQ AKTS opened at $18.15 on Friday. The business has a fifty day moving average price of $22.96 and a two-hundred day moving average price of $22.12. The stock has a market capitalization of $975.56 million and a PE ratio of -22.13. Aktis Oncology has a fifty-two week low of $14.72 and a fifty-two week high of $34.19.

Aktis Oncology (NASDAQ:AKTS - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The firm had revenue of $3.38 million during the quarter, compared to the consensus estimate of $2.70 million. As a group, sell-side analysts expect that Aktis Oncology will post -1.85 earnings per share for the current year.

About Aktis Oncology

Aktis Oncology, Inc is a clinical-stage biopharmaceutical company developing targeted alpha therapies for the treatment of cancer. Its research is focused on creating therapies designed to selectively deliver alpha-particle radiation to tumor cells while limiting exposure to surrounding healthy tissue.

The company's platform uses proprietary tumor-targeting molecules, including engineered miniproteins, to bind specific targets found on cancer cells and transport radioactive payloads to tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.